Title of Invention

A PROCESS FOR THE PREPARATION OF IODIXANOL

Abstract A PROCESS FOR THE PREPARATION OF IODIXANOL
Full Text FORM 2
THE PATENTS ACT 1970
[39 OF 1970]
&
THE PATENTS RULES, 2003
COMPLETE SPECIFICATION
[See Section 10; rule 13]
"A PROCESS FOR THE PREPARATION OF lODIXANOL"
AMERSHAM HEALTH AS. (formerly known as NYCOMED IMAGING AS), a Norwegian company of Nycoveien 2, 0485 Oslo, Norway

The following specification particularly describes the invention and the manner in which it is to be performed:


The present invention relates to a process for the preparation of iodixanol.
This invention is concerned with the synthesis of iodixanol.
Iodixanol (1,3-bis(acetamido)-N,N"-bis[3,5-bis(2,3-dihydroxypropylaminocarbonyl) -2 ,4, 6-triiodophenyl] -2-hydroxypropane) is a non-ionic X-ray cpntrast agent which is currently manufactured in large quantities, A number of methods are known for its preparation but these are all multistep processes and the cost of the final formulated product thus mainly depends on these processes. It is therefore important to optimise these processes for both economic and environmental reasons,.
Three main processes are known for the preparation of iodixanol, all of which start with 5-nitroisophthalic acid. In the first process (NO 161358) , the following route is used, via the final intermediate 5-acetamido-N,N" -bis(2,3-dihydroxypropyl) -2,4, 6-triiodo-isophthalamide ("Compound A"):


WO 00/47549 ^ PCT/GB00/00113

lodixanol
The problem with this process is that a yield of only
18% is reported in the given example, and the product is purified by preparative chromatography. When we have repeated the example, we have found that the low yield is due to incomplete conversion (dimerisation) of
Compound A to iodixanol. After 40-60% of the starting material is consumed, over-alkylation of iodixanol starts to dominate over the desired reaction, causing the net content of iodixanol in the reaction mixture to decrease. In fact, 40-60% conversion to iodixanol seems
to be the maximum obtainable. Due to this low
conversion, common crystallisation techniques are not able to purify the product to the necessary level, and preparative liquid chromatography is the only way to obtain a pure product. The combination of low yields
with an expensive purification method such as
preparative chromatography is a serious disadvantage in an industrial process.
Priebe et.al. (Acta Radiol. 36 (1995), Suppl. 399, 21- 31) describe another route which avoids the difficult last step of the above process. However, the route involves eight reaction steps from 5-nitroisophthalic acid, which is undesirable, and one of the steps includes chlorination with thionyl chloride, which is extremely corrosive. Also, the introduction of the iodine atoms takes place very early in the sequence, which is disadvantageous as iodine is the most expensive
3

-WO 00/47549

reagent in the process. The yield and final purification method for this route have not been reported.
The third route to iodixanol involves the synthesis of 5-amino-2,4,6-triiodoisophthalic acid (WO 96/37458) and then its dichloride (WO 96/37459), followed by conversion into Compound A (US 5705692) and finally dimerisation as in the first process above. This method thus has the same disadvantages as the first, and also uses an undesirable acid chlorination step.
We have now surprisingly found that unreacted Compound A from one dimerisation batch, as produced for example in the first and third processes described above, can be recovered from the reaction mixture by a very simple process, and reused in a later batch. This increases the net yield from successive batches on an industrial scale dramatically. Additionally, the removal of most of the unreacted Compound A from the reaction mixture allows the expensive preparative liquid chromatography purification to be replaced by conventional crystallisation methods, still providing iodixanol suitable for pharmaceutical use.
The invention thus provides a process for the preparation of iodixanol by dimerisation of Compound A in which, after the dimerisation step, unreacted Compound A is precipitated from the reaction mixture and recovered for re-use.
The dimerisation step itself may be carried out as described in No 161368 and WO 98/23296, for example
using epichlorohydrin, 1,3-dichloro-2-hydroxypropane or 1, 3 dibromo-2-hydroxypropane as the dimerisation agent. The reaction is usually carried out in a non-aqueous solvent such as a Cl.6 alcohol, preferably 2-
4



WO 00/17510
methoxyethanol or methanol, and generally results in the conversion of 40-60% of Compound A to iodixanol. Dimerisation in pure water or mixtures of water and one or more alcohols (e.g. C1-6alkanols) is also possible.
Precipitation of Compound A from a non-aqueous reaction mixture can be effected after addition of water, for example in an amount of 1-2, preferably 1.3-1.8 L/kg Compound A used as starting material. If water is present in the reaction mixture, the amount of water added for precipitation can be reduced accordingly. An alcoholic co-solvent (e.g. a C1-6 alkanol such as methanol) may additionally be used, for example in an amount of 0.5-2, preferably 0.8-1.5 L/kg Compound A used as starting material. In some instances, traces of undissolved material remain after the addition of water and alcohol and these can be dissolved by addition of alkali, e.g. sodium hydroxide. The pH of the solution is then adjusted to about 10-11 by addition of an acid, e.g. hydrochloric acid, to provoke precipitation of unreacted Compound A and if necessary the temperature can be adjusted to 15-40°C, preferably 18-30°C. The solution is optionally seeded with crystals of Compound A to initiate the precipitation of Compound A, while the iodixanol formed stays in solution.
Further addition of acid to a pH of 2-5, preferably 3-4, can increase the yield of the recovery process by increasing the supersaturation of non-ionic Compound A. After this final pH adjustment, the suspension is advantageously stirred for some hours to enhance the precipitation of Compound A, e.g. 4-30 hours, preferably 8-20 hours. The precipitate should then be separated from the reaction mixture by a conventional technique, such as centrifugation or filtration, and optionally washed with a suitable solvent, e.g. water or methanol.

5




W0 00/47549 PCT/GB00/004413
The filtrate from the separation mainly contains iodixanol and small fractions of related iodinated aromatic compounds, in addition to salts and remaining epichlorohydrin and derivatives thereof. This mixture can be purified by conventional desalination and crystallisation methods to obtain iodixanol suitable for pharmaceutical use. chromatographic purification of the crude iodixanol in the filtrate is not necessary.
The separated Compound A from the recovery process can optionally be recrystallised for example from water/methanol or another alkanol. Thus, the moist material from the filtration/centrifugation may be dissolved in water in the presence of alkali. The amount of water should be about 2-7 1/kg of Compound A, preferably 3-5 1/kg. Alkali, e.g. aqueous sodium hydroxide, should be added until all traces of undissolved material are removed. The solution may optionally be filtered to remove remaining traces of undissolved matter. An alcohol, e.g. methanol (0.5-1.5 1/kg of Compound A, preferably 0.5-1.0 litres/kg) may then be added, and the mixture heated to 40-80°C, preferably 50-60°C. Adjustment of pH by an acid, e.g. hydrochloric acid, causes pure Compound A to precipitate. The mixture may optionally be seeded with a small amount of Compound A crystals. Maximum yield from the recrystallisation is obtained if the pH is finally adjusted to about 5-7, e.g. with hydrochloric acid, followed by cooling to 10-25°C. The slurry may optionally be stirred at this temperature to enhance the crystallisation, e.g. 2-18 hours. The precipitate is separated from the suspension by any conventional technique, for instance centrifugation or filtration, and optionally washed with water, methanol or another suitable alkanol. The recovered Compound A may advantageously be dried, e.g. under reduced pressure, before reuse in a hew dimerisation.


6



WO 00/47549 PCT/GB00/00413
Recovered Compound A, together if necessary with further fresh Compound A, may be used in a new dimerisation reaction as described above, followed by subsequent recovery of unreacted Compound A. The invention thus also includes process in which iodixanol is prepared in a series of successive processes according to the invention in which, after the dimerisation, unreacted Compound A is precipitated from the reaction mixture and recovered, optionally crystallised, and then re-used in a subsequent process in the series. The dimerisation reactions in such a series will normally be substantially identical, and the unreacted Compound A will normally be recovered after each dimerisation step.
The following examples illustrate the invention.
"EXAMPLE 1
Compound A (366 g) was dissolved in a solution of NaOH(23 g) in 2-methoxyethanol (360 ml) at 50°C. The temperature was decreased to 15°C when all solids were dissolved, and conc. HC1 (28 g) was added to the solution. Epichlorohydrin (13 g) was added in one portion, and the reaction was monitored by HPLC. After 46 hours the content of iodixanol in the reaction mixture was 49.6%. Water (575 ml) was added, and the temperature was increased to 19°C. The solution was at this time clear, so no further addition of sodium hydroxide was necessary. The pH was adjusted to 10.8 by 18% hydrochloric acid, and the solution seeded with 1 g of Compound A. The pH of the resulting suspension was further pH-adjusted with 18% hydrochloric acid to pH 4.0. The suspension was left with stirring overnight before filtration and washing with water (60 ml) on the filter. The filtrate was further desalinated and crystallised by conventional methods, providing iodixanol suitable for pharmaceutical use. The material








7



PCT/GB00/00413
on the filter was analysed on HPLC, showing 94.3% Compound A and 5.1% iodixanol.
EXAMPLE 2
The recovered Compound A from Example 1 was taken directly from the filter without drying, and completely dissolved in water (440 ml) and 50% aqueous NaOH (15 ml) . The solution was filtered through a 3 pm filter to
remove traces of insoluble matter, and some more water
(50 ml) was added to the filtrate. Methanol (95, ml) was added to the solution, and the temperature was increased to 60°C. The pH was reduced from 11.5 to 9.8 with 18% hydrochloric acid, and 0.8 g seeds of Compound A was
added. After 3 0 minutes, the pH was further reduced to 6 with 18% hydrochloric acid. The temperature was gradually reduced to 15°C, and the precipitated material was filtered, washed with methanol (140 ml) and dried under vacuum at 60 °C. The yield of pure Compound A (
99% by HPLC) was 118 g, corresponding to 32% of the starting material in Example 1.
The recovered Compound A (118 g) was combined with fresh Compound A (248 g) in a new dimerisation similar to Example 1, giving nearly identical results as in Example 1.













8


WE CLAIM
1. A process for the preparation of iodixanol by dimerisation of 5-
acetamido-N,N"-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-isophthalamide
( Compound A") in which, after the dimerisation step, unreacted Compound A is precipitated from the reaction mixture and recovered for re-use.
2. A process as claimed in claim 1 in which the dimerisation step is carried out using epichlorohydrin, l,3-dichloro-2-hydroxypropane or 1,3-dibromo-2-hydroxypropane as the dimerisation agent in a non-aqueous solvent or in water or a mixture of water and one or more alcohols.
3. A process as claimed in claim 2 in which the dimerisation agent is epichlorohydrin and the solvent is 2-methoxyethanol or methanol.
4. A process as claimed in any preceding claim in which precipitation of Compound A is effected with water, optionally together with an alcoholic co-solvent.
5. A process as claimed in claim 4 in which the pH of the mixture is adjusted to 10-11 with acid to provoke precipitation, the temperature adjusted if necessary to 15-40°C and the solution optionally seeded with crystals of Compound A.
6. A process as claimed in claim 5 in which further acid is added to a pHof2-5.
7. A process as claimed in any preceding claim in which the Compound A recovered is recrystallised.
9

8. A process as claimed in claim 1 in which, after separation of Compound A, the iodixanol-containing mixture is purified without the use of chromatographic methods.
9. A process as claimed in any preceding claim in which the recovered Compound A is re-used in a subsequent process for the preparation of iodixanol.
10. A process in which iodixanol is prepared in a series of successive processes as claimed in any of claims 1 to 8 in which, after the dimerisation, unreacted Compound A is precipitated from the reaction mixture and recovered, optionally crystallised, and then re-used in a subsequent process in the series.
Dated this 01st day of August, 2001.

10

Documents:

in-pct-2001-00921-mum-cancelled pages(1-8-2001).pdf

in-pct-2001-00921-mum-claims(granted)-(9-3-2005).pdf

in-pct-2001-00921-mum-correspondence(ipo).pdf

in-pct-2001-00921-mum-correspondence.pdf

in-pct-2001-00921-mum-form 1(1-8-2001).pdf

in-pct-2001-00921-mum-form 1(15-3-2005).pdf

in-pct-2001-00921-mum-form 1(9-3-2005).pdf

in-pct-2001-00921-mum-form 13(15-3-2005).pdf

in-pct-2001-00921-mum-form 13(8-8-2002).pdf

in-pct-2001-00921-mum-form 19(20-2-2004).pdf

in-pct-2001-00921-mum-form 2(granted)-(9-3-2005).pdf

in-pct-2001-00921-mum-form 3(1-8-2001).pdf

in-pct-2001-00921-mum-form 3(16-3-2005).pdf

in-pct-2001-00921-mum-form 3(9-3-2005).pdf

in-pct-2001-00921-mum-form 5(1-8-2001).pdf

in-pct-2001-00921-mum-form-pct-ipea-409(2-8-2001).pdf

in-pct-2001-00921-mum-form-pct-isa-210(2-8-2001).pdf

in-pct-2001-00921-mum-petition under rule 137(9-3-2005).pdf

in-pct-2001-00921-mum-petition under rule 138(9-3-2005).pdf

in-pct-2001-00921-mum-power of authority(2-8-2001).pdf

in-pct-2001-00921-mum-power of authority(9-3-2005).pdf

in-pct-2002-00921-mum-claims(granted)-(09-03-2005).doc

in-pct-2002-00921-mum-form 2(granted)-(09-03-2005).doc


Patent Number 203122
Indian Patent Application Number IN/PCT/2001/00921/MUM
PG Journal Number 15/2007
Publication Date 13-Apr-2007
Grant Date 31-Oct-2006
Date of Filing 01-Aug-2001
Name of Patentee AMERSHAM HEALTH AS
Applicant Address NYCOVEIEN 1-2, N-0401 OSLO, NORWAY
Inventors:
# Inventor's Name Inventor's Address
1 OLE MANGE HOMESTAD NYCOMED IMAGING AS, LINDESNES-FABRIKKER, N-4510 SPANGEREID, NORWAY
PCT International Classification Number N/A
PCT International Application Number N/A
PCT International Filing date 2000-02-10
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 9903109.8 1999-02-11 U.K.